Discussion about this post

User's avatar
Edwin's avatar

Become a permanent patient?

If I could afford it, and I can't, I would still pass.

Expand full comment
Sounds Like Nonsense's avatar

Aʟᴢʜᴇɪᴍᴇʀ Exᴘᴇʀᴛ & Bʀᴀɪɴ Mɪᴄʀᴏʙɪᴏᴍᴇ Exᴘᴇʀᴛ

Frank Bernier, PhD, MSc, CIP

https://www.linkedin.com/posts/francois-bernier-phd_donanemab-visual-guide-to-the-phase-3-trial-activity-7086842390757408768-vebM

The Emperor has no clothes, isn't it?

Check the excellent visual abstract below showing the effect of donanemab which is in line to get FDA approval later this year after lecanemab recent approval.

Now you know the limited efficacy and potential risks associated with anti-amyloid antibodies. On the other hand, the advantages of probiotics Bifidobacterium breve appear significantly more promising. Our recent randomized placebo-controlled double-blind clinical trials have yielded noteworthy results:

The daily consumption of Bifidobacterium breve has proven to be more effective in enhancing cognition and preventing 100% brain atrophy in subjects with Mild Cognitive Impairment (MCI).

Effect of Probiotic Bifidobacterium breve in Improving Cognitive Function and Preventing Brain Atrophy in Older Patients with Suspected Mild Cognitive Impairment: Results of a 24-Week Randomized, Double-Blind, Placebo-Controlled Trial

https://pubmed.ncbi.nlm.nih.gov/35570493/

1ST TRIAL

Probiotic Bifidobacterium breve in Improving Cognitive Functions of Older Adults with Suspected Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial

https://pubmed.ncbi.nlm.nih.gov/32623402/

Expand full comment
4 more comments...

No posts